| |
Main Study Cohorta
|
High Cardiovascular Risk Cohortb
|
Statin Initiator Cohortc
|
|---|
|
Cancer Survivor
|
Control
|
Cancer Survivor
|
Control
|
Cancer Survivor
|
Control
|
|---|
|
n = 131,676
|
n = 3,324,152
|
n = 4202
|
n = 113,035
|
n = 12,142
|
n = 366,280
|
|---|
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
|---|
|
Sex
|
|
Male
|
58,587 (44.7)
|
1,618,820 (48.70)
|
2659 (63.3)
|
80,264 (71.0)
|
5959 (49.1)
|
194,430 (53.1)
|
|
Female
|
72,823 (55.3)
|
1,705,299 (51.30)
|
1543 (36.7)
|
32,771 (29.0)
|
6183 (50.9)
|
171,848 (46.9)
|
|
Age (years)
|
|
Median (IQR)
|
66.5 (57.5–75.5)
|
50.5 (42.1–62.3)
|
69.1 (64.2–72.9)
|
64.2 (58.4–69.8)
|
68.9 (62.4–75.1)
|
62.6 (54.9–70.2)
|
|
40–49
|
14,117 (10.7)
|
1,529,272 (46.0)
|
27 (0.6)
|
5410 (4.8)
|
351 (2.9)
|
45,132 (12.3)
|
|
50–59
|
24,564 (18.6)
|
775,972 (23.3)
|
368 (8.8)
|
27,121 (24.0)
|
1630 (13.4)
|
96,664 (26.7)
|
|
60–69
|
38,078 (28.9)
|
521,777 (15.7)
|
1815 (43.2)
|
50,847 (45.0)
|
4393 (36.2)
|
125,540 (34.3)
|
|
70–79
|
33,983 (25.8)
|
303,231 (9.1)
|
1765 (42.0)
|
26,713 (23.6)
|
4086 (33.7)
|
73,598 (20.1)
|
|
80+
|
20,934 (15.9)
|
193,900 (5.8)
|
227 (5.4)
|
2944 (2.6)
|
1682 (13.7)
|
25,346 (6.9)
|
|
BMI (kg/m2)
|
|
Mean (SD)
|
26.9 (5.3)
|
26.9 (5.3)
|
28.3 (4.8)
|
27.8 (5.1)
|
28.2 (5.4)
|
28.7 (5.6)
|
|
< 18.5
|
2748 (2.1)
|
48,109 (1.4)
|
50 (1.2)
|
897 (0.8)
|
131 (1.1)
|
2906 (0.8)
|
|
18.5–25
|
46,037 (35.0)
|
1,130,838 (34.0)
|
1127 (26.8)
|
27,294 (24.2)
|
3175 (26.9)
|
86,962 (24.5)
|
|
≥ 25
|
74,375 (56.5)
|
1,736,648 (52.2)
|
2925 (69.6)
|
81,734 (72.3)
|
8504 (72.0)
|
265,128 (74.7)
|
|
Missing
|
8516 (6.5)
|
408,557 (12.3)
|
100 (2.4)
|
3113 (2.8)
|
332 (2.7)
|
11,285 (3.1)
|
|
Cholesterol (mmol/L)
|
|
Mean (SD)
|
5.3 (1.2)
|
5.4 (1.1)
|
5.7 (1.0)
|
5.8 (1.1)
|
6.0 (1.3)
|
6.1 (1.3)
|
|
Normal (< 5)
|
42,503 (32.3)
|
796,230 (23.9)
|
898 (21.4)
|
21,543 (19.1)
|
2242 (18.7)
|
58,780 (16.2)
|
|
Mod (5–8)
|
62,529 (47.5)
|
1,405,997 (42.3)
|
3137 (74.6)
|
85,221 (75.4)
|
8965 (74.8)
|
278,848 (76.9)
|
|
High (> 8)
|
1704 (1.5)
|
38,297 (1.2)
|
92 (2.2)
|
3316 (2.9)
|
775 (6.47)
|
25,032 (6.9)
|
|
Missing
|
24,940 (18.9)
|
1,083,578 (32.6)
|
75 (1.8)
|
2955 (2.6)
|
157 (1.29)
|
3640 (1.0)
|
|
Smoking status
|
|
Never
|
46,606 (35.4)
|
1,358,706 (40.9)
|
1194 (28.4)
|
29,306 (25.9)
|
3729 (30.7)
|
118,728 (32.4)
|
|
Ex
|
61,969 (47.1)
|
965,510 (29.1)
|
2133 (50.8)
|
46,494 (41.2)
|
6572 (54.1)
|
166,482 (45.5)
|
|
Current
|
22,627 (17.2)
|
885,915 (26.6)
|
875 (20.8)
|
37,190 (32.9)
|
1840 (15.2)
|
80,841 (22.1)
|
|
Missing
|
474 (0.4)
|
114,021 (3.4)
|
< 5
|
45 (0.0)
|
< 5
|
299 (0.1)
|
|
Alcohol status (non- ex- current drinker)
|
|
Non
|
25,030 (19.0)
|
577,211 (17.4)
|
742 (17.7)
|
18,139 (16.1)
|
2500 (27.3)
|
75,516 (27.5)
|
|
Ex
|
3778 (2.84)
|
74,249 (2.2)
|
162 (3.9)
|
4079 (3.6)
|
447 (4.9)
|
13,002 (4.7)
|
|
Current
|
|
light
|
48,354 (36.7)
|
1,042,681 (31.3)
|
1629 (38.8)
|
40,996 (36.3)
|
4868 (53.1)
|
140,039 (51.0)
|
|
moderate
|
4776 (3.6)
|
106,934 (3.2)
|
224 (5.3)
|
5904 (5.2)
|
503 (5.5)
|
15,837 (5.8)
|
|
heavy
|
5025 (3.8)
|
150,372 (4.5)
|
254 (6.0)
|
9229 (8.2)
|
562 (6.1)
|
19,668 (7.2)
|
|
unknown
|
2819 (2.1)
|
74,769 (2.3)
|
117 (2.8)
|
4193 (3.7)
|
280 (3.1)
|
10,747 (3.9)
|
|
Missing
|
41,894 (31.8)
|
1,297,936 (39.0)
|
1074 (25.6)
|
30,495 (27.0)
|
2982 (24.6)
|
91,474 (25.0)
|
|
Medical history
|
|
Diabetes
|
12,045 (9.2)
|
153,405 (4.6)
|
187 (4.5)
|
5308 (4.7)
|
2239 (18.4)
|
69,156 (18.9)
|
|
CKD
|
9577 (7.3)
|
28,419 (0.9)
|
368 (8.8)
|
5465 (4.8)
|
1450 (12.0)
|
24,464 (6.7)
|
|
Chronic liver disease
|
2223 (1.7)
|
39,429 (1.2)
|
75 (1.8)
|
7975 (1.8)
|
221 (1.8)
|
6378 (1.7)
|
|
Index of Multiple Deprivation quintile
|
|
1 (least)
|
16,993 (12.9)
|
298,566 (9.0)
|
641 (15.2)
|
12,842 (11.4)
|
1697 (11.1)
|
40,458 (11.1)
|
|
2
|
12,043 (12.9)
|
340,205 (10.2)
|
588 (14.0)
|
13,616 (12.6)
|
1607 (13.2)
|
43,074 (11.8)
|
|
3
|
18,708 (14.2)
|
384,484 (11.6)
|
545 (13.0)
|
14,211 (12.6)
|
1655 (13.6)
|
48,491 (13.2)
|
|
4
|
64,007 (48.6)
|
1,978,653 (59.5)
|
1894 (45.1)
|
57,464 (50.8)
|
5615 (46.2)
|
188,142 (51.4)
|
|
5 (most)
|
14,985 (11.4)
|
322,244 (9.7)
|
434,534 (12.7)
|
14,902 (13.2)
|
1586 (13.1)
|
46,115 (12.6)
|
|
Calendar year
|
|
2005–07
|
62,916 (47.8)
|
2,423,116 (72.9)
|
623 (14.8)
|
23,020 (20.4)
|
4105 (33.8)
|
156,589 (42.8)
|
|
2008–10
|
34,416 (26.1)
|
471,289 (14.2)
|
1681 (40.0)
|
48,349 (42.8)
|
4310 (35.5)
|
124,339 (33.9)
|
|
2011–13
|
34,344 (26.1)
|
429,747 (12.9)
|
1898 (45.2)
|
41,666 (36.9)
|
3727 (30.7)
|
85,352 (23.3)
|
- aCovariates were measured at baseline (or closest recording) defined in the ‘main study cohort’ as the date of the start of unexposed (non-cancer) and exposed (≥ 1 year post cancer diagnosis) follow-up time. Patients in the Main Study Cohort could contribute person-time to exposed and unexposed cohorts
- bBaseline was defined in the ‘high cardiovascular risk cohort’ as the date of the first high cardiovascular risk score. Patients could only be included in one of the comparison cohorts
- cBaseline was defined in the ‘statin initiator cohort’ as the date of the first statin prescription. Patients could only be included one of the comparison cohorts. If a non-cancer patient developed cancer while on statin therapy they were censored
